Transplant rejection

Rare Biomarkers Specimen Collection and Stabilization Market to Reach USD 54.2 Billion, Globally, by 2031 at 8.7% CAGR: Allied Market Research

Retrieved on: 
Friday, October 7, 2022

PORTLAND, Ore., Oct. 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Rare Biomarkers Specimen Collection and Stabilization Market by Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), by Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), by Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.

Key Points: 
  • According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.
  • However, the tedious and lengthy process for development of biomarkers and high cost of the development restrain the market growth.
  • The Covid-19 pandemic made a positive impact on the global rare biomarkers specimen collection and stabilization market, owing to surge in prevalence of rare diseases and innovations in diagnosis of diseases using biomarkers.
  • Rare biomarkers specimen collection and stabilization are utilized for determining what the coronavirus does to the body and how the body reacts on infection.

Benzinga: Oncocyte Reports It's Ready To Enter The $3.6 Billion Transplant Diagnostics Market In First Half Of 2022

Retrieved on: 
Tuesday, May 10, 2022

NEW YORK , May 10, 2022 /PRNewswire/ -- The transplant diagnostics market encompasses blood tests, genetic sequencing, and other technology to monitor transplant patients and predict complications to make sure their bodies don't reject new organs or tissue.

Key Points: 
  • NEW YORK, May 10, 2022 /PRNewswire/ -- The transplant diagnostics market encompasses blood tests, genetic sequencing, and other technology to monitor transplant patients and predict complications to make sure their bodies don't reject new organs or tissue.
  • The market was estimated at $3.6 billion in 2019 and is projected to reach $5.5 billion by 2025 as access to lifesaving transplant procedures increases and faster, less complicated, diagnostic tools are developed.
  • Oncocyte Corp.,a company focused primarily on the immune therapy diagnostics market, is setting its sights on the rapidly growing transplant diagnostics market after its acquisition of Chronix Biomedical early last year.
  • The TheraSure Transplant Monitor has not been cleared or approved by the US Food and Drug Administration.

Global Cell-Free DNA Isolation and Extraction Market (2021 to 2031) - Focus on Consumables, Platform, Techniques, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, February 7, 2022

The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market.

Key Points: 
  • The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market.
  • The global cell-free DNA isolation and extraction market comprise well-established and newly emerging companies.
  • What are the major market drivers, challenges, and opportunities in the global cell-free DNA isolation and extraction market?
  • What are the underlying structures resulting in the emerging trends within the global cell-free DNA isolation and extraction market?

U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients

Retrieved on: 
Tuesday, July 20, 2021

NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for PROGRAF® (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients.

Key Points: 
  • "The current approval expands the indications for PROGRAF from liver, kidney and heart transplants to adult and pediatric patients who receive a lung transplant in combination with other medicines to help prevent organ rejection."
  • The FDA granted Orphan Drug Designation (ODD) to PROGRAF for the prevention of rejection after lung transplant in September 2019.
  • PROGRAFis a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart or lung transplants, in combination with other immunosuppressants.
  • PROGRAF is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney, liver, heart or lung transplant.

Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology

Retrieved on: 
Wednesday, June 2, 2021

primary investigator and adjunct assistant professor, Baylor College of Medicine Nephrology Division, and Kidney Hypertension Transplant Clinic of Clearlake Specialties.

Key Points: 
  • primary investigator and adjunct assistant professor, Baylor College of Medicine Nephrology Division, and Kidney Hypertension Transplant Clinic of Clearlake Specialties.
  • Expanding datasets from the PROTECT trial indicated that KRYSTEXXA could represent a durable and tolerable therapy for this sensitive patient population.
  • Horizon is currently conducting Phase 2 clinical trials with HZN4920 in Sjgrens syndrome , rheumatoid arthritis and kidney transplant rejection .
  • Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.

Palmetto GBA Finalizes Local Coverage Determination (LCD) for Liquid Biopsies for Solid Organ Transplantation, Including Immucor’s kSORT Assay

Retrieved on: 
Monday, April 26, 2021

b'NORCROSS, Ga., April 26, 2021 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced that Palmetto MolDX has finalized a local coverage determination (LCD) for Molecular Testing for Solid Organ Allograft Rejection.

Key Points: 
  • b'NORCROSS, Ga., April 26, 2021 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced that Palmetto MolDX has finalized a local coverage determination (LCD) for Molecular Testing for Solid Organ Allograft Rejection.
  • kSORT is a non-invasive gene expression assay designed to improve patient outcomes.
  • To learn more, visit www.immucor.com .\nkSORT is a 15-gene RNA expression-based assay designed for enhanced post-transplant graft surveillance and immune quiescence monitoring in solid organ transplant patients.
  • kSORT is available exclusively through Immucor DX, the company\xe2\x80\x99s CLIA certified and CAP accredited independent clinical laboratory as a Laboratory Developed Test (LDT).\n'

Polyneuron and University of Basel Awarded Grant of CHF 1.2M to Advance Novel Treatments to Support ABO-Incompatible Transplants

Retrieved on: 
Wednesday, April 14, 2021

The project will advance the development of novel injectable glycopolymers to support better ABO-incompatible (ABOi) transplantation patient outcomes.

Key Points: 
  • The project will advance the development of novel injectable glycopolymers to support better ABO-incompatible (ABOi) transplantation patient outcomes.
  • However, ABOi transplants require powerful immunosuppression to prevent transplant rejection caused by the recipient\xe2\x80\x99s antibodies (isoagglutinins), which can lead to serious infections.
  • This implies that these patients are under strong treatment schedules for their primary diseases, including severe adverse effects and co-morbidities.
  • Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication.

CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings

Retrieved on: 
Monday, April 5, 2021

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundations 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundations 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.
  • As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host Next Generation Care for Kidney Transplant Patients, a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time.
  • In addition, CareDx is sponsoring the Diagnosis of Acute Rejection in Kidney Transplantation: A Clinical Update, a continuing medical education (CME) program on April 8th from 12:301:30 p.m. Eastern Time.
  • We are excited to showcase the latest in kidney transplant surveillance data at this great event.

eGenesis Expands Research Collaboration with Leading Academic Medical Center

Retrieved on: 
Thursday, April 1, 2021

The expanded collaboration now includes preclinical research of gene-edited kidneys implanted in non-human primate (NHP) recipients, which builds on the original research collaboration for the implantation of the Companys gene-edited pancreatic islet cells in NHPs that began in 2020.

Key Points: 
  • The expanded collaboration now includes preclinical research of gene-edited kidneys implanted in non-human primate (NHP) recipients, which builds on the original research collaboration for the implantation of the Companys gene-edited pancreatic islet cells in NHPs that began in 2020.
  • Professor of Surgery in the School of Medicine, and Executive Director of the Duke Transplant Center, will lead the research.
  • Michael Curtis, Ph.D., President of Research & Development of eGenesis added, The Duke Medical team under Dr. Knechtles leadership is a leading transplant program with strong research capabilities in preventing organ rejection.
  • This collaboration will accelerate research and validation of our gene edited kidneys, leading to their evaluation in clinical trials.

Transplant Genomics Welcomes New President And Senior Leaders

Retrieved on: 
Tuesday, March 2, 2021

Transplant Genomics, Inc. ("TGI") is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy.

Key Points: 
  • Transplant Genomics, Inc. ("TGI") is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy.
  • Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status.
  • Our flagship product is TruGraf, the only non-invasive blood test approved by CMS that offers the earliest possible detection of "silent" subclinical acute rejection in kidney transplant recipients with stable graft function.
  • It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies.